SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news

 

 

Drugs moving into the clinic: 11

By Mike Nagle , 24-Apr-2007

The eleventh in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.

Sponsor Name Indication Mechanism
Array BioPharma & AstraZeneca ARRY-704 (AZD8330) Oncology - undisclosed but preclinical studies in melanoma, pancreatic, colon, lung, and breast cancers MEK inhibitor - MEK regulates cell proliferation and survival as part of the Ras/Raf/MEK/ERK pathway.
Poniard Pharmaceuticals Oral picoplatin Oncology - various solid tumours Cytotoxic platinum compound - causes cell death by binding to DNA and interfering with DNA replication and transcription N.B. other Phase I & II clinical trials for intravenous formulation
Kalypsys KD7040 Neuropathic pain Topical inducible nitric oxide synthase (iNOS) inhibitor
Hadasit Bio-Holdings & Verto Lupusorb Autoimmune - Lupus Device with specific peptide (VRT101 - from C terminal of laminin) to remove disease-causing auto-antibodies from the blood during plasmapheresis. N.B. Combined Phase I/II trial
Addex Pharmaceuticals ADX48621 CNS - primarily depression but also potentially generalised anxiety disorder and inflammatory pain Negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5)

Key Industry Events